Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI) that is approved by die FOOD and Drug Administration (FDA) for the treatment of obsessive-compulsive disorder and is used for other conditions, including depression. Fluvoxamine is not FDA-approved for the treatment of any infection. (fluvoxamine, 2021)

There’s not enough evidence for the COVID-19 Treatment Guidelines Panel to recommend either for or against the use of fluvoxamine for the treatment of COVID-19. Results from adequately powered, well-designed, and well-conducted clinical trials are needed to provide more specific, evidence-based guidance on the role of fluvoxamine for the treatment of COVID-19. (fluvoxamine, 2021)

Treatearly.org. 2021. fluvoxamine. [online] Available at: <https://www.treatearly.org/fluvoxamine> [Accessed 25 October 2021].